BALPHARMA.NS BALPHARMA NSE
₹90.12
-8.41% 1Y
Market & Price
Market Cap
-
Current Price
₹90.12
High / Low (52W)
₹105.16 / ₹60.42
Beta
-
Valuation
Stock P/E
-
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
₹-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
16.93%
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
₹1.12
EPS (TTM)
₹-
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
₹335.69 Cr
Current Assets
₹234.87 Cr
Working Capital
₹15.37 Cr
Ownership
Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
-
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Growth (CAGR)
Revenue 5Y
1.71%
Profit 5Y
8.74%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Ad space
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 73.15 Cr | 73.07 Cr | 65.87 Cr | 74.02 Cr | 87.69 Cr |
| Cost of Revenue | - | 36.85 Cr | 47.36 Cr | 33.54 Cr | 39.94 Cr | 46.16 Cr |
| Gross Profit | - | 36.30 Cr | 25.71 Cr | 32.33 Cr | 34.09 Cr | 41.53 Cr |
| Operating Expenses | - | 31.23 Cr | 19.93 Cr | 28.79 Cr | 30.63 Cr | 35.21 Cr |
| Operating Income | - | 5.07 Cr | 5.77 Cr | 3.54 Cr | 3.46 Cr | 6.32 Cr |
| EBITDA | - | 8.26 Cr | 6.41 Cr | 6.78 Cr | 6.85 Cr | 9.87 Cr |
| Interest Expense | - | 5.01 Cr | 1.63 Cr | 4.05 Cr | 3.86 Cr | 4.85 Cr |
| Pretax Income | - | 56.63 L | 2.59 Cr | 20.85 L | 71.73 L | 1.79 Cr |
| Tax Provision | - | 4.84 L | -2.83 Cr | 0 | 0 | 0 |
| Net Income | - | 48.12 L | 5.43 Cr | 20.06 L | 70.95 L | 1.78 Cr |
| Diluted EPS | 0.65 | 0.33 | - | 0.13 | 0.45 | 1.12 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 279.70 Cr | 301.71 Cr | 326.35 Cr | 294.27 Cr |
| Cost of Revenue | 167.82 Cr | 176.24 Cr | 195.19 Cr | 161.28 Cr |
| Gross Profit | 111.88 Cr | 125.46 Cr | 131.16 Cr | 132.99 Cr |
| Operating Expenses | 96.82 Cr | 107.92 Cr | 109.38 Cr | 112.89 Cr |
| Operating Income | 15.06 Cr | 17.55 Cr | 21.77 Cr | 20.10 Cr |
| EBITDA | 27.10 Cr | 24.37 Cr | 32.02 Cr | 29.45 Cr |
| Interest Expense | 8.88 Cr | 10.50 Cr | 12.90 Cr | 14.54 Cr |
| Pretax Income | 9.18 Cr | 4.75 Cr | 9.05 Cr | 5.14 Cr |
| Tax Provision | 3.48 Cr | 2.13 Cr | 1.60 Cr | -2.10 Cr |
| Net Income | 5.61 Cr | 2.57 Cr | 7.39 Cr | 7.22 Cr |
| Diluted EPS | 3.79 | 1.67 | 4.96 | 4.54 |
Compounded Sales Growth
| 5 Years: | 1.71% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 8.74% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -8.41% |
| 6 Months: | +15.92% |
| 3 Months: | +15.79% |
| 1 Month: | +18.33% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 260.53 Cr | 313.17 Cr | 319.84 Cr | 335.69 Cr |
| Current Assets | 184.57 Cr | 228.16 Cr | 234.16 Cr | 234.87 Cr |
| Cash & Equivalents | 1.11 Cr | 1.49 Cr | 4.20 Cr | 1.75 Cr |
| Inventory | 74.40 Cr | 98.00 Cr | 87.81 Cr | 103.02 Cr |
| Receivables | 75.31 Cr | 93.98 Cr | 99.62 Cr | 92.44 Cr |
| Total Liabilities | 202.04 Cr | 249.47 Cr | 247.87 Cr | 258.29 Cr |
| Current Liabilities | 165.64 Cr | 209.33 Cr | 203.06 Cr | 219.50 Cr |
| Long Term Debt | 27.01 Cr | 30.52 Cr | 36.35 Cr | 31.40 Cr |
| Total Debt | 106.66 Cr | 133.08 Cr | 142.25 Cr | 152.31 Cr |
| Total Equity | 58.63 Cr | 63.79 Cr | 72.00 Cr | 77.42 Cr |
| Shares Outstanding | 1.56 Cr | 1.57 Cr | 1.58 Cr | 1.59 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 26.80 Cr | -1.54 Cr | 22.81 Cr | 20.32 Cr |
| Investing Cash Flow | -9.48 Cr | -22.18 Cr | -18.89 Cr | -14.92 Cr |
| Financing Cash Flow | -17.22 Cr | 24.09 Cr | -1.21 Cr | -7.84 Cr |
| Capital Expenditure | -8.47 Cr | -14.65 Cr | -10.98 Cr | -18.79 Cr |
| Free Cash Flow | 18.33 Cr | -16.18 Cr | 11.83 Cr | 1.53 Cr |
| Net Change in Cash | 8.92 L | 37.43 L | 2.71 Cr | -2.44 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 40.0% | 41.6% | 40.2% | 45.2% |
| Operating Margin % | 5.4% | 5.8% | 6.7% | 6.8% |
| Net Margin % | 2.0% | 0.9% | 2.3% | 2.5% |
| ROE % | 9.6% | 4.0% | 10.3% | 9.3% |
| ROCE % | 15.9% | 16.9% | 18.6% | 17.3% |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BALPHARMA
No recent headlines available.